{
    "id": "60c69cc4-203a-4d95-a834-ca6a7eb3ab8b",
    "indications": "norethindrone ethinyl estradiol tablets ( chewable ) 0.8 mg/0.025 mg ferrous fumarate tablets ( chewable ) 75 mg indicated women prevent pregnancy . efficacy norethindrone ethinyl estradiol tablets ( chewable ) 0.8 mg/0.025 mg ferrous fumarate tablets ( chewable ) 75 mg women body mass index ( bmi ) > 35 kg/m2 evaluated .",
    "contraindications": "• chew one tablet without water time every day . ( 2.1 ) • take tablets order directed blister pack . ( 2.1 )",
    "adverseReactions": "norethindrone ethinyl estradiol tablets ( chewable ) ferrous fumarate tablets ( chewable ) contraindicated females known develop following conditions : •a high risk arterial venous thrombotic diseases . examples include women known : osmoke , age 35 [ boxed warning , ( 5.1 ) ] ohave deep vein thrombosis pulmonary embolism , past [ ( 5.1 ) ] ohave cerebrovascular disease [ ( 5.1 ) ] ohave coronary artery disease [ ( 5.1 ) ] ohave thrombogenic valvular thrombogenic rhythm diseases heart ( example , subacute bacterial endocarditis valvular disease , atrial fibrillation ) [ ( 5.1 ) ] ohave inherited acquired hypercoagulopathies [ ( 5.1 ) ] ohave uncontrolled hypertension [ ( 5.5 ) ] ohave diabetes vascular disease [ ( 5.7 ) ] ohave headaches focal neurological symptoms migraine headaches without aura age 35 [ ( 5.8 ) ] •current diagnosis , history , breast cancer , may hormone-sensitive [ ( 5.2 ) ] •liver tumors , benign malignant , liver disease [ ( 5.3 ) , ( 8.7 ) , pharmacology ( 12.3 ) ] •undiagnosed abnormal uterine bleeding [ ( 5.9 ) ] •pregnancy , reason cocs pregnancy [ ( 5.9 ) ( 8.1 ) ] •use hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir , due potential alt elevations [ ( 5.4 ) ]",
    "ingredients": [],
    "organization": "Mylan Pharmaceuticals Inc.",
    "name": "NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE",
    "effectiveTime": "20240115",
    "indications_original": "Norethindrone and ethinyl estradiol tablets (chewable) 0.8 mg/0.025 mg and ferrous fumarate tablets (chewable) 75 mg are indicated for use by women to prevent pregnancy. \n                  The efficacy of norethindrone and ethinyl estradiol tablets (chewable) 0.8 mg/0.025 mg and ferrous fumarate tablets (chewable) 75 mg in women with a body mass index (BMI) of > 35 kg/m2 has not been evaluated.",
    "contraindications_original": "• Chew one tablet without water at the same time every day. ( 2.1 ) • Take tablets in the order directed on the blister pack. ( 2.1 )",
    "adverseReactions_original": "Norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) are contraindicated in females who are known to have or develop the following conditions: \n                  \n                     \n                        •A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:s\n                           \n                              oSmoke, if over age 35 [see Boxed Warning, and Warnings and Precautions (5.1)] \n                           \n                           \n                              oHave deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)] \n                           \n                           \n                              oHave cerebrovascular disease [see Warnings and Precautions (5.1)] \n                           \n                           \n                              oHave coronary artery disease [see Warnings and Precautions (5.1)] \n                           \n                           \n                              oHave thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)]\n                           \n                           \n                              oHave inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)] \n                           \n                           \n                              oHave uncontrolled hypertension [see Warnings and Precautions (5.5)] \n                           \n                           \n                              oHave diabetes with vascular disease [see Warnings and Precautions (5.7)] \n                           \n                           \n                              oHave headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings and Precautions (5.8)] \n                           \n                        \n                     \n                     \n                        •Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions (5.2)] \n                     \n                     \n                        •Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.3), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)] \n                     \n                     \n                        •Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.9)] \n                     \n                     \n                        •Pregnancy, because there is no reason to use COCs during pregnancy [see Warnings and Precautions (5.9) and Use in Specific Populations (8.1)] \n                     \n                     \n                        •Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.4)]"
}